SPPI - Spectrum Pharmaceuticals down 2% post-market despite Q4 2021 earnings beat

Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are down 2% in post-market trading even though its Q4 2021 results beat on the bottom line. Its net loss in the quarter of ~$39.7M was nearly the same as the ~$39.8M loss in the year-ago period. On a per share basis, net loss was -$0.26 compared to -$0.29 in Q4 2020. The company did not report any revenue in the quarter. The company ended the year with $88.5M in cash. Looking ahead to later this year, Spectrum (SPPI) is awaiting an FDA decision by Nov. 24, 2022, on its New Drug Application for poziotinib in previously treated patients with non-small cell lung cancer. Read why Seeking Alpha contributor Avisol Capital Partners considers Spectrum (SPPI) a hold.

For further details see:

Spectrum Pharmaceuticals down 2% post-market despite Q4 2021 earnings beat